Skip to main content
Erschienen in: Indian Journal of Gastroenterology 4/2019

10.08.2019 | Original Article

Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?

verfasst von: D. K. S. Kannangara, M. D. S. Lokuhetty, D. Subasinghe, Y. I. N. S. Gunawardene, R. S. Dassanayake

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification are/is linked to a dismal outcome of gastric carcinoma (GCa). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are key methods to identify patients for HER2 targeted therapy. Drawbacks of both the methods warrant novel tests. Hence, we evaluated the value of quantitative real-time polymerase chain reaction (qPCR) as an alternative test method, relative to IHC to detect HER2 status of GCa and to find relationship between these  results with demographic/clinicopathological data.

Method

Twenty GCa patients with known IHC HER2 scores were evaluated. qPCR was performed for the HER2 gene and amyloid precursor protein (reference gene) in formalin-fixed paraffin-embedded GCa tissue. Cycle threshold values (Ct) were analyzed using the Pfaffl method to detect HER2 gene amplification.

Results

HER2 positivity rates by IHC and qPCR were 20% and 35%, respectively. The sensitivity and specificity of qPCR were 67% and 76%, respectively, relative to IHC. qPCR results were reproducible. The diagnostic consistency between IHC and qPCR (κ = 0.146) was slightly agreeable (0.01 < k < 0.20), with a 65% concordance. Based on McNemar’s test, there was no significant difference between the results of the two tests. IHC HER2 protein expression had relationship with the tumor (TNM) stage and Lauren histological type (p < 0.05). Positive HER2 gene expression by qPCR showed relationship with depth of invasion, lymph node involvement, and degree of differentiation (p < 0.05).

Conclusion

Cost-effective qPCR could serve as an alternative test method for detection of HER2 status of GCa. Both HER2 overexpression by IHC and gene amplification by qPCR are associated with adverse clinicopathological features.
Literatur
1.
Zurück zum Zitat Stewart B, Wild CP. World cancer report 2014. Lyon: IARC Press; 2014. Stewart B, Wild CP. World cancer report 2014. Lyon: IARC Press; 2014.
2.
Zurück zum Zitat Fernando E, Perera S, Amarasinghe H, et al. Cancer incidence data Sri Lanka. 10th ed. Sri Lanka: National Cancer Control Programme: Ministry of Health and Indigenous Medicine; 2014. Fernando E, Perera S, Amarasinghe H, et al. Cancer incidence data Sri Lanka. 10th ed. Sri Lanka: National Cancer Control Programme: Ministry of Health and Indigenous Medicine; 2014.
3.
4.
Zurück zum Zitat Hamilton SR, Aaltonen LA. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. Hamilton SR, Aaltonen LA. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.
5.
Zurück zum Zitat Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRef Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRef
6.
Zurück zum Zitat Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev. 2011;12:1417–23.PubMed Wang S, Zheng G, Chen L, Xiong B. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev. 2011;12:1417–23.PubMed
7.
Zurück zum Zitat Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21–6. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21–6.
8.
Zurück zum Zitat Dennis JS, Brian LJ, Steven S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.CrossRef Dennis JS, Brian LJ, Steven S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.CrossRef
9.
Zurück zum Zitat Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor- associated protease systems. J Clin Oncol. 2000;18:2201–9. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor- associated protease systems. J Clin Oncol. 2000;18:2201–9.
10.
Zurück zum Zitat Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: inter-observer variability and performance of immunohistochemistry with four antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14:1079–86. Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: inter-observer variability and performance of immunohistochemistry with four antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14:1079–86.
11.
Zurück zum Zitat Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307.
12.
Zurück zum Zitat Dietrich D, Uhl B, Sailer V, et al. Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition. PLoS One. 2013;8:e77771. Dietrich D, Uhl B, Sailer V, et al. Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition. PLoS One. 2013;8:e77771.
13.
Zurück zum Zitat Zhu GJ, Xu CW, Fang MY, et al. Detection of Her-2/neu expression in gastric cancer: quantitative PCR versus immunohistochemistry. Exp Ther Med. 2014;8:1501–7.CrossRef Zhu GJ, Xu CW, Fang MY, et al. Detection of Her-2/neu expression in gastric cancer: quantitative PCR versus immunohistochemistry. Exp Ther Med. 2014;8:1501–7.CrossRef
14.
Zurück zum Zitat Hans O, Agneta J, Birgitta H, et al. Methods for evaluating HER2 status in breast cancer: comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue. Pathol Lab Med Int. 2013;5:31–7. Hans O, Agneta J, Birgitta H, et al. Methods for evaluating HER2 status in breast cancer: comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue. Pathol Lab Med Int. 2013;5:31–7.
15.
Zurück zum Zitat Hillig T, Thode J, Breinholt MF, et al. Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer. APMIS. 2012;120:1000–7. Hillig T, Thode J, Breinholt MF, et al. Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer. APMIS. 2012;120:1000–7.
16.
Zurück zum Zitat Davis MB, Liu X, Wang S, Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013;12:40. Davis MB, Liu X, Wang S, Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013;12:40.
17.
Zurück zum Zitat Koltz BR, Hicks DG, Whitney M. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. Biotech Histochem. 2012;87:40–5.CrossRef Koltz BR, Hicks DG, Whitney M. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. Biotech Histochem. 2012;87:40–5.CrossRef
18.
Zurück zum Zitat Titus K. Second act for HER2, in gastric cancers. CAP Today. 2014; pp. 1–36. Titus K. Second act for HER2, in gastric cancers. CAP Today. 2014; pp. 1–36.
19.
Zurück zum Zitat Stanek L, Rozkos T, Laco J, et al. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. Mol Med Rep. 2014;10:2669–74.CrossRef Stanek L, Rozkos T, Laco J, et al. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. Mol Med Rep. 2014;10:2669–74.CrossRef
20.
Zurück zum Zitat Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe. 2010;31:208–17.CrossRef Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe. 2010;31:208–17.CrossRef
21.
Zurück zum Zitat Joaquín A, José B, Kim P, Josep P. p95HER2 and breast cancer. Cancer Res. 2011;71:1515–9.CrossRef Joaquín A, José B, Kim P, Josep P. p95HER2 and breast cancer. Cancer Res. 2011;71:1515–9.CrossRef
22.
Zurück zum Zitat Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol. 2006;6:2. Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol. 2006;6:2.
23.
Zurück zum Zitat Sheng WQ, Huang D, Ying JM, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24:2360–4.CrossRef Sheng WQ, Huang D, Ying JM, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24:2360–4.CrossRef
24.
Zurück zum Zitat Laboissiere RS, Buzelin MA, Balabram D, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol. 2015;15:157. Laboissiere RS, Buzelin MA, Balabram D, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol. 2015;15:157.
Metadaten
Titel
Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?
verfasst von
D. K. S. Kannangara
M. D. S. Lokuhetty
D. Subasinghe
Y. I. N. S. Gunawardene
R. S. Dassanayake
Publikationsdatum
10.08.2019
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 4/2019
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-019-00955-6

Weitere Artikel der Ausgabe 4/2019

Indian Journal of Gastroenterology 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.